Please enter keyword
OK
Please enter keyword
OK
By technologies
Site-specific gene modification usually uses homologous recombination of genomic DNA with exogenous DNA. Gene editing is developed from homologous recombination (HR) in mouse embryonic stem cells (ESCs), and the emergence of DNA nuclease-based gene-editing has brought new changes to the technology. Compared with ZFN and TALEN, CRISPR/Cas9 technology is more efficient, shortens the timeline, reduces the R&D cost, breaks species constraints, and also has the potential to directly edit genes in patient tissues.
Biocytogen developed an innovative CRISPR/Cas9-based Extreme Genome Editing (EGE™) system, which can knock in large DNA fragments (> 5 kb) in the genomes of mice, rats, and cell lines for up-to 20-fold more efficiently than conventional CRISPR/Cas9 methods, minimizing the timeline to generate genetically engineered animal and cell line models.